The Wegovy medication name explained: brand, ingredient, and what that means for you

What the STEP 1 trial actually showed about semaglutide

The clearest way to understand the medical name behind Wegovy and what it refers to is to start with the evidence that earned it its UK licence. The STEP 1 trial, published in the New England Journal of Medicine, randomised adults with obesity or overweight with at least one weight-related condition to semaglutide 2.4 mg or placebo for 68 weeks. Those on semaglutide achieved an average weight reduction of around 15%, compared with roughly 2.4% on placebo. That dataset underpinned NICE's recommendation of semaglutide for weight management (TA875) and its UK licensing as Wegovy.

The injectable version works as a once-weekly subcutaneous injection. Semaglutide binds GLP-1 receptors in the gut, pancreas and brain, signalling satiety, slowing how quickly the stomach empties, and reducing the drive to eat. The result is a sustained calorie deficit without requiring constant conscious restriction.

In June 2026 a second formulation arrived: Wegovy tablets, taken orally once daily. These use the same active molecule co-formulated with an absorption enhancer called SNAC. The MHRA approved them on 11 June 2026, making the UK the first country in Europe to licence an oral GLP-1 medicine for weight management. The maintenance dose for the tablet is 25 mg, a number that looks very different from the injection's 2.4 mg, but the two schedules are not equivalent; they are separate formulations calibrated differently. If you are curious about which form might suit you, a detailed overview of both Wegovy formulations sets out what each involves.

Semaglutide by other names: Ozempic, Rybelsus, and where Wegovy fits

Semaglutide appears under several brand names in the UK, and confusion between them is one of the questions our prescribers hear regularly. The short version: the molecule is the same, but the licences are not.

Ozempic is semaglutide in a once-weekly injectable pen, licensed by the MHRA for type 2 diabetes. It is not licensed for weight loss. Prescribing it for weight management would be off-label, and nume does not supply it for that purpose. The NHS medicines page for semaglutide explains both Ozempic and Wegovy in plain terms, and it is worth reading if you have seen both names and wondered whether they are the same thing.

Rybelsus is oral semaglutide, taken daily, licensed for type 2 diabetes at 3 mg, 7 mg and 14 mg. Those three strengths are sometimes mistakenly described as part of the Wegovy tablet dose ladder, but they are not. The Wegovy weight-management tablet starts at 1.5 mg, escalates through 4 mg and 9 mg, and reaches a 25 mg maintenance dose. The Rybelsus strengths exist in an entirely separate licensed context. If you are researching oral semaglutide for weight loss specifically, a guide to semaglutide's various UK product names unpicks the distinctions clearly.

The practical upshot: when a prescriber writes Wegovy on a prescription, they are specifying a licensed weight-management product. That precision matters for supply chain integrity, dispensing accuracy and your safety.

What Wegovy's eligibility criteria look like in practice

Because semaglutide is a prescription-only medicine, no pharmacy can dispense it without a valid prescription following clinical assessment. The licensed eligibility criteria for Wegovy (injection) cover adults with a BMI of 30 or above, or a BMI between 27 and 29.9 accompanied by at least one weight-related condition such as high blood pressure, high cholesterol, prediabetes or obstructive sleep apnoea. For the tablet, the licensed threshold is broadly the same.

NICE's recommendation under TA875 applies stricter criteria for NHS access: semaglutide is recommended on the NHS only within a specialist weight management service, for a maximum of two years, and at a BMI of 35 or above with at least one comorbidity (or lower thresholds under NICE's ethnic-background adjustments). Private treatment through a regulated online pharmacy sits outside those NHS criteria, which is relevant for people who do not meet the NHS threshold or who prefer not to wait. The Wegovy treatment overview covers NHS and private routes side by side.

Lower BMI thresholds can apply for some ethnic backgrounds under UK clinical guidance, and the prescriber considers the full picture rather than BMI alone. A prescriber at a GPhC-registered pharmacy reviews every application individually before any prescription is issued.

Practical details: what using Wegovy actually looks like

The injectable version comes as a pre-filled pen; each pen holds four weekly doses. Treatment starts at 0.25 mg, escalating in roughly four-weekly steps through 0.5 mg, 1.0 mg, 1.7 mg and 2.4 mg. In January 2026 the MHRA also approved a 7.2 mg dose (the highest available), and a dedicated single-dose 7.2 mg pen received approval on 14 April 2026. Specific pen formats and dose availability are confirmed at the time of consultation rather than stated in advance, supply and clinical suitability both affect what is prescribed.

If you order through a registered pharmacy, the pen arrives by tracked courier in plain, unbranded packaging. With DPD you will get a one-hour window the morning it is due, so you do not need to stay in all day. The pen itself is stored in the fridge; the Patient Information Leaflet covers the exact room-temperature window if you need to travel with it.

Common side effects are led by the gastrointestinal system: nausea, loose stools, constipation and indigestion are all reported, typically most noticeable in the first weeks or after a dose step up. Most people find they settle. For context on what to expect across the treatment journey, a page on what kind of medicine Wegovy is covers the mechanism and side-effect profile in more depth. You can also explore the weight-loss treatments available through nume to see how semaglutide sits alongside other options.

If you are weighing up what private treatment costs, an honest breakdown of what the price typically includes across providers is on our Wegovy cost guide, it is worth reading before making any decisions on that basis alone.

When you are ready to find out whether Wegovy is clinically suitable for you, check your eligibility through our free consultation. A GPhC-registered prescriber reviews every application personally, the same day.